Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.
about
Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetesLinagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study
P2860
Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Design, statistical analysis a ...... versus voglibose and placebo.
@en
Design, statistical analysis a ...... versus voglibose and placebo.
@nl
type
label
Design, statistical analysis a ...... versus voglibose and placebo.
@en
Design, statistical analysis a ...... versus voglibose and placebo.
@nl
prefLabel
Design, statistical analysis a ...... versus voglibose and placebo.
@en
Design, statistical analysis a ...... versus voglibose and placebo.
@nl
P2093
P2860
P921
P356
P1433
P1476
Design, statistical analysis a ...... versus voglibose and placebo.
@en
P2093
Klaus Dugi
Masahiro Takeuchi
Naoyuki Hayashi
Yoshiharu Horie
P2860
P2888
P356
10.1186/1745-6215-10-82
P577
2009-09-05T00:00:00Z
P5875
P6179
1023713444